Evaxion Biotech AS (EVAX)
1.42
+0.05
(+3.65%)
USD |
NASDAQ |
Nov 22, 16:00
1.42
0.00 (0.00%)
After-Hours: 20:00
Evaxion Biotech Total Liabilities (Quarterly): 15.18M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 15.18M |
| June 30, 2024 | 13.98M |
| March 31, 2024 | 22.65M |
| December 31, 2023 | 17.63M |
| September 30, 2023 | 14.68M |
| June 30, 2023 | 14.22M |
| March 31, 2023 | 13.91M |
| December 31, 2022 | 13.72M |
| September 30, 2022 | 13.90M |
| Date | Value |
|---|---|
| June 30, 2022 | 13.85M |
| March 31, 2022 | 14.69M |
| December 31, 2021 | 7.726M |
| September 30, 2021 | 7.466M |
| June 30, 2021 | 5.828M |
| March 31, 2021 | 7.121M |
| December 31, 2020 | 4.927M |
| September 30, 2020 | 3.372M |
| December 31, 2019 | 1.722M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
1.722M
Minimum
Dec 2019
22.65M
Maximum
Mar 2024
11.48M
Average
13.88M
Median
Total Liabilities (Quarterly) Benchmarks
| Ascendis Pharma AS | 1.330B |
| DBV Technologies SA | 39.02M |
| Adaptimmune Therapeutics PLC | 237.45M |
| Akari Therapeutics PLC | 9.428M |
| Biodexa Pharmaceuticals PLC | 6.628M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 15.18M |
| Shareholders Equity (Quarterly) | 0.074M |
| Net Debt Paydown Yield | 7.96% |